Liuqi Zhao, Qijun Wang, Guirong Liang, Yuxi Zhou, Nam Yiu, Baoqi Yang, Guiying Zhang, Wei Li, Suying Feng, Panpan Shang, Xixue Chen, Xuejun Zhu, Jie Zheng, Meng Pan, Mingyue Wang
IMPORTANCE: Dupilumab is a theoretically novel therapy for bullous pemphigoid (BP). However, its effectiveness and safety have yet to be confirmed in a large-scale study. OBJECTIVE: To assess the efficacy and safety of dupilumab in patients with BP and evaluate factors that potentially affect short-term and long-term outcomes. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted from January 1, 2021, to July 31, 2022...
September 1, 2023: JAMA Dermatology